close

Enter

Log in using OpenID

Bric Diabetes Drugs Market Poised to Expand at a Robust Pace By 2021

embed
In recent years, there has been an increased use of diabetes drugs due to rising prevalence of diabetes in various age groups. Increasing aging population, technological advancements, and increasing sales of novel drugs are some of the key factors
Diabetes is a chronic disease characterized by high blood sugar level. It is caused by the improper
functioning of the pancreas which secretes insulin. Diabetes is also known as diabetes mellitus.
High blood sugar leads to increased thirst and hunger, and frequent urination. Lack of treatment for
diabetes causes several complications such as diabetes ketoacidosis, heart disease, stroke, and
kidney failures. Insulin infusion therapy is used to treat diabetes. There are three types of diabetes
including type1, type 2, and gestational diabetes. Type 1 diabetes, also known as insulin dependent
diabetes or juvenile diabetes, is characterized by low production of insulin by the body. Some of the
conditions which lead to type 1 diabetes are addisons disease, celiac disease, rheumatoid arthritis,
and autoimmune thyroid disease.
Request Report for TOC @ https://www.persistencemarketresearch.com/toc/3888
Type 2 diabetes is the most common type of diabetes, predominant in overweight and obese people.
Pancreatectomy, chronic pancreatitis, and cystic fibrosis are some of the conditions which lead to
Type2 diabetes. Diabetes is treated through diabetes drugs such as insulin, metformin, and
sulphonylureas. Diabetes drugs help in preventing complications and controlling blood glucose
level in the blood. Some of the drugs used to treat type 2 diabetes are metformin, actos, avandia,
lantus subcutaneous, and invokana. All drugs are administered orally except insulin, exenatide,
liraglutide, and pramlintide. Insulin is delivered through insulin delivery devices including infusion
pump, intravenous sets, insulin syringe, insulin pen, and jet injectors. Long acting, intermediate
acting, short acting, and rapid acting are some of the types of insulin used to treat diabetes.
China and India are dominating the BRIC diabetes drug market due to increasing diabetic
population and increasing aging population in these regions. In addition, rising funds for diabetes
control is also boosting growth of the diabetes drugs market in India. Brazil is expected to show
lower growth rate due to patent expiry of various diabetes drugs.
Request To Sample of Report @ https://www.persistencemarketresearch.com/samples/3888
In recent years, there has been an increased use of diabetes drugs due to rising prevalence of
diabetes in various age groups. Increasing aging population, technological advancements, and
increasing sales of novel drugs are some of the key factors driving growth of the BRIC diabetes
drugs market. In addition, government initiatives to control diabetes are also fueling growth of the
BRIC diabetes drugs market. However, high manufacturing cost of drugs and insulin devices is
restraining growth of the BRIC diabetes drugs market. In addition, low awareness among people
regarding diabetes treatment is also restraining growth of the BRIC diabetes drugs market.
Maintaining safety and security of patients while using diabetes drugs and drug infusion devices
could be a challenge for growth of the BRIC diabetes drugs market. One of the recent trends in the
BRIC diabetes drugs market is rising use of personalized drugs. Some of the companies operating in
the BRIC diabetes drugs market are Abbott Laboratories, Biocon, Ltd, Eli Lilly and Company,
Lupin, Ltd., and Sun Pharma Industries, Ltd. Other companies in the market include Bayer
Healthcare AG, Roche Holding AG, Novo Nordisk A/S, and Aurobindo Pharma, Ltd.
Pre Book Full Report @ https://www.persistencemarketresearch.com/checkout/3888
Author
vinay
vinay247   documents Email
Document
Category
Health and Medicine
Views
10
File Size
28 KB
Tags
drugs
1/--pages
Report inappropriate content